ALEXANDER ROTENBERG

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology BOSTON, MA NPI 1154348043

General Payments — all program years on this page

$35,833.25

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 39
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $16,589.05 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $15,430.984
Travel and Lodging $757.024
Food and Beverage $401.059

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $9,056.0012
F. Hoffmann-La Roche AG $4,485.002
Alkermes, Inc. $2,899.981
SK Life Science, Inc. $148.072

By program year

Program yearAmountRecords
2018 $2,490.693
2019 $3,699.3611
2020 $5,318.833
2022 $7,681.023
2023 $54.302
2024 $16,589.0517

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1120584483 Alkermes, Inc. $2,899.98 02/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1132973833 F. Hoffmann-La Roche AG $2,070.00 07/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1132973835 F. Hoffmann-La Roche AG $2,415.00 10/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137664994 Takeda Pharmaceuticals U.S.A., Inc. $437.40 05/13/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137664996 Takeda Pharmaceuticals U.S.A., Inc. $41.24 05/17/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137664998 Takeda Pharmaceuticals U.S.A., Inc. $49.99 05/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665000 Takeda Pharmaceuticals U.S.A., Inc. $49.99 05/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665002 Takeda Pharmaceuticals U.S.A., Inc. $22.36 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665004 Takeda Pharmaceuticals U.S.A., Inc. $26.84 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665006 Takeda Pharmaceuticals U.S.A., Inc. $74.99 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665008 Takeda Pharmaceuticals U.S.A., Inc. $17.89 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665010 Takeda Pharmaceuticals U.S.A., Inc. $10.92 05/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137665012 Takeda Pharmaceuticals U.S.A., Inc. $189.55 05/18/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137665014 Takeda Pharmaceuticals U.S.A., Inc. $88.83 05/19/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137665016 Takeda Pharmaceuticals U.S.A., Inc. $8,046.00 05/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1154129617 SK Life Science, Inc. $23.10 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154129757 SK Life Science, Inc. $124.97 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.